logo
ProjectOngoing

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

Sector: Nuclear • Location: Norway, Türkiye, Germany

Source: EU Funding & Tenders Portal

The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose. In the NOVO project, we will develop the first proof-of-concept of an RDV technology adaptable to any PT treatment and bring the concept to TRL

Status
Under Construction
Sector
Nuclear, Hospital, Electric Vehicles (EVs), Automotive, Government
Location
Norway, Türkiye, Germany
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY” is an infrastructure initiative in the Nuclear sector, located in Norway, Türkiye, Germany. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose. In the NOVO project, we will develop the first proof-of-concept of an RDV technology adaptable to any PT treatment and bring the concept to TRL 4 by also considering integration into the PT clinical workflow. The RDV technology will be pivotal for enabling the next generation of adaptive PT therapy, i.e., dose-guided real-time adaptive therapy. Real-time measurement of the dose to targeted and non-targeted tissues will be the key to truly empower patient-centered, personalized cancer treatment, important to improve curation and quality-of-life post-treatment. As a high-risk/high-gain project, NOVO aims at a first-of-its-kind RDV technology through the unique synergy between (1) cutting-edge, inexpensive organic scintillator technology that can detect secondary radiation during treatment for non-invasive measurements, (2) novel and fast image reconstruction, artificial intelligence (AI)-accelerated models and AI-enhanced image reconstruction to allow simultaneous detection of multiple radiation species and tissue compositional analysis, (3) tumor-tracking and imaging of tissue radio-sensitivity based on oxygen levels, (4) intelligent automation of decision-making schemes for real-time dose-guided adaptive therapy. The project will essentially open a new era in PT that enables curing more cancer patients and reducing toxicity from treatment. The NOVO consortium covers the entire value chain of RDV development (technology providers, theory and modelling, technology integration and PT clinics) and optimally engages nuclear, medical, and high-energy physicists, chemists, mathematicians, computer scientists, oncologists, biologists, as well as European PT centers.

Location

Country

Norway, Türkiye, Germany

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Nuclear, Hospital, Electric Vehicles (EVs), Automotive, Government

Article published date

2026-02-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project